Format

Send to

Choose Destination
EBioMedicine. 2017 Feb;16:87-100. doi: 10.1016/j.ebiom.2017.01.021. Epub 2017 Jan 17.

MeCP2 Promotes Gastric Cancer Progression Through Regulating FOXF1/Wnt5a/β-Catenin and MYOD1/Caspase-3 Signaling Pathways.

Author information

1
Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Shaanxi, Xi'an 710061, People's Republic of China; Key Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education of China, Shaanxi, Xi'an 710061, People's Republic of China.
2
Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Shaanxi, Xi'an 710061, People's Republic of China.
3
Department of Oncology Surgery, the First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Shaanxi, Xi'an 710061, People's Republic of China.
4
Key Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education of China, Shaanxi, Xi'an 710061, People's Republic of China.
5
Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Shaanxi, Xi'an 710061, People's Republic of China; Key Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education of China, Shaanxi, Xi'an 710061, People's Republic of China. Electronic address: hchen@xjtu.edu.cn.

Abstract

Methyl-CpG binding protein 2 (MeCP2) has recently been characterized as an oncogene frequently amplified in several types of cancer. However, its precise role in gastric cancer (GC) and the molecular mechanism of MeCP2 regulation are still largely unknown. Here we report that MeCP2 is highly expressed in primary GC tissues and the expression level is correlated with the clinicopathologic features of GC. In our experiments, knockdown of MeCP2 inhibited tumor growth. Molecular mechanism of MeCP2 regulation was investigated using an integrated approach with combination of microarray analysis and chromatin immunoprecipitation sequencing (ChIP-Seq). The results suggest that MeCP2 binds to the methylated CpG islands of FOXF1 and MYOD1 promoters and inhibits their expression at the transcription level. Furthermore, we show that MeCP2 promotes GC cell proliferation via FOXF1-mediated Wnt5a/β-Catenin signaling pathway and suppresses apoptosis through MYOD1-mediated Caspase-3 signaling pathway. Due to its high expression level in GC and its critical function in driving GC progression, MeCP2 represents a promising therapeutic target for GC treatment.

KEYWORDS:

Caspase-3; FOXF1; Gastric cancer; MYOD1; MeCP2; Wnt5a

PMID:
28131747
PMCID:
PMC5474507
DOI:
10.1016/j.ebiom.2017.01.021
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center